65934-61-4|RU 24926|3,3'-((propylazanediyl)bis(ethane-2,1-diyl))diphenol|-范德生物科技公司

RU 24926

NMR下载 COA and HPLC MSDS下载
names：
3,3'-((propylazanediyl)bis(ethane-2,1-diyl))diphenol
CAS号：
65934-61-4
MDL Number：
MF(分子式)： C19H25NO2 MW(分子量)： 299.41
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	3,3'-((propylazanediyl)bis(ethane-2,1-diyl))diphenol
英文别名	RU 24926; RU24926; RU-24926;
CAS号	65934-61-4
Inchi	InChI=1S/C19H25NO2/c1-2-11-20(12-9-16-5-3-7-18(21)14-16)13-10-17-6-4-8-19(22)15-17/h3-8,14-15,21-22H,2,9-13H2,1H3
InchiKey	RVXNTMVFBHOIKH-UHFFFAOYSA-N
分子式 Formula	C19H25NO2
分子量 Molecular Weight	299.41
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	RU 24926(CAS:65934-61-4):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	RU 24926 is a di-(phenethyl)-amine derivative that acts as a dopamine-D2 receptor agonist.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Dean B, Srikanthan P, Copolov DL. Inhibition of [3H]dopamine uptake by platelets by the dopamine-D2 receptor agonist RU 24926. J Pharm Pharmacol. 1991 Jan;43(1):56-7. PubMed PMID: 1676063.

[2]Fortin M, Degryse M, Petit F, Hunt PF. The dopamine D2 agonists RU 24213 and RU 24926 are also kappa-opioid receptor antagonists. Neuropharmacology. 1991 Apr;30(4):409-12. PubMed PMID: 1677169.

[3] Suaudeau C, Costentin J. Analgesic effect of the direct D2 dopamine receptor agonist RU 24926 and cross tolerance with morphine. Fundam Clin Pharmacol. 1995;9(2):147-52. PubMed PMID: 7628827.

[4] Simon P, Charpentier S, Costentin J. An automated method for the assessment of spontaneous and stereotyped climbing behavior in mice. Effects of the selective D1- and D2-dopamine receptor agonists SKF-38393 and RU-24926 and their association. Methods Find Exp Clin Pharmacol. 1991 Mar;13(2):99-104. PubMed PMID: 1830125.

[5] Johnson EA, Tsai CE, Lucci J, Harrison-Shahan Y, Azzaro AJ. Dopamine D2 synthesis-modulating receptors are present in the striatum of the guinea pig. Neuropharmacology. 1992 Jan;31(1):95-101. PubMed PMID: 1347405.

6: Conzelmann U, Holland A, Meyer DK. Effects of selective dopamine D2-receptor agonists on the release of cholecystokinin-like immunoreactivity from rat neostriatum. Eur J Pharmacol. 1984 May 18;101(1-2):119-25. PubMed PMID: 6235119.7: Vasse M, Protais P. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. Neuropharmacology. 1989 Sep;28(9):931-9. PubMed PMID: 2554186.8: Suaudeau C, Dourmap N, Costentin J. Rapid and long lasting reduction of the hypothermic effect of a D2 dopamine agonist after an intracerebroventricular injection of 6-hydroxydopamine. Neuropharmacology. 1995 Jan;34(1):101-5. PubMed PMID: 7623958.9: Sokoloff P, Riou JF, Martres MP, Schwartz JC. Presence of dopamine D-2 receptors in human tumoral cell lines. Biochem Biophys Res Commun. 1989 Jul 31;162(2):575-82. PubMed PMID: 2527031.10: Yarbrough GG, McGuffin-Clineschmidt J, Singh DK, Haubrich DR, Bendesky RJ, Martin GE. Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists. Eur J Pharmacol. 1984 Mar 16;99(1):73-8. PubMed PMID: 6723791.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开